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Abstract
Background: Total hip replacement (THR) is the preferred method for the active and lucid elderly patient with a
displaced femoral neck fracture (FNF). But controversy still exists regarding using cemented or uncemented stem in
these patients. The aim of this study is to compare a cemented and uncemented femoral stem in patients 65–79 years
treated surgically with THR for displaced FNF.
Methods/design: In a single-centre, single-blinded, randomized controlled trial, we will include 140 patients aged 65-
79 years with an acute displaced FNF and randomize them in a 1:1 ratio to a cemented tapered or a uncemented
tapered hydroxyapatite - coated femoral stem. A cemented cup will be used in both groups. The patients will be
blinded for allocation. The primary endpoints will be the incidence of all hip-related complications and health-related
quality of life evaluated with EuroQol-5D (EQ-5D) index up to 2 years after surgery. Secondary outcomes will be overall
mortality, general medical complications and hip function. The follow-up will be at 3 months, 1 and 2 years.
Further follow-ups after end of study will be at 4 and 10 years. Results will be analysed using 95 % CI’s for the
effect size. A regression model will also be used to adjust for stratification factor.
Discussion: The ethical committee at Karolinska Institutet has approved the study. An interim analysis on the
primary endpoints will be performed when half the sample size is included. The results from the study will
be disseminated to the medical community via presentations and publications in relevant medical journals.
The study will provide evidence if a cemented or uncemented femoral stem is preferable in THR for elderly patients
with a displaced FNF.
Trial registration: The trial is registered at clinicaltrials.gov (NCT02247791), October 21, 2013.
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Background
Total hip replacement (THR) is the preferred method
for the active and lucid elderly patient with a displaced
femoral neck fracture (FNF) [1, 2]. Comparisons between
cemented and uncemented stems in hip arthroplasty for
patients with a FNF have almost consistently favoured
cemented fixation, mainly because of greater deterioration
in pain, walking ability, use of walking aids and activity of
daily living [3] and because of a higher incidence of hip
related complication such as periprosthetic fracture [4]
for uncemented implants. Despite this, recent reports
on modern, hydroxyapatite-coated femoral stems used
for this patient-group have shown promising early re-
sults [5-7]. In addition, bone cement implantation syn-
drome (BCIS), is more prevalent in cemented than in
uncemented stems [8]. It is also a commonly occurring
phenomenon in patients treated for FNF with cemented
arthroplasty and severe BCIS has a significant impact
on early and late mortality [9]. Thus, the use of unce-
mented stems for this patient group may still be
justified.
We hypothesized that an uncemented, proximally por-
ous and hydroxyapatite coated femoral stem used in THR
for a displaced FNF would not be associated with more
adverse peri- and postoperative hip-related complications
compared with a THR using cemented stem, and that the
health-related quality of life for the patients would be
equivalent at 2 years.
Methods/design
Trial design, settings and location
This single centre, single-blinded, prospective randomized
controlled trial will be performed between 2009 and
2025 at the Orthopaedic department Danderyd Hospital,
Stockholm, Sweden. Danderyd Hospital is an emer-
gency regional teaching hospital affiliated with the
Karolinska Institute and has a catchment area of
approximately 500,000 inhabitants. The guidelines of
Good Clinical Practise (ICH-GCP) will be followed [10].
The Local Ethics Committee at Karolinska Institute ap-
proved the protocol. The guidelines of the CONSORT
Statement will be followed [11] for the final paper and the
SPIRIT guidelines for the study protocol [12].
Randomization and blinding
The patients will be block-randomized in a 1:1 ratio, to
receive either cemented or uncemented stem. We will
use sealed envelopes and randomization will be stratified
by sex to ensure that the sex distribution will be the
same in both groups. The study subjects will be blinded to
choice of treatment. To verify that the blinding is main-
tained during the study, the patients will be asked if they
knew their assigned allocation arm at the 2-year follow-
up. The surgeons and staff are not blinded during the
study.
Study subjects and eligibility criteria
All patients with a displaced FNF who are admitted to
Danderyd Hospital will be screened for participation in
the study. Research nurses who identify eligible patients
before surgery screen all patients at arrival to the hospital.
The first author (G.C.) or one of the other co-authors will
include patients and acquire informed consent. All who
agree to participate and give their oral and written in-
formed consent will be included if they fulfil the inclusion
criteria. The inclusion criteria are an acute (within 48 h)
displaced FNF (Garden III to IV) [13] after a low-energy
trauma (i.e. fall), an age 65–79 years, no concurrent joint
disease or previous fracture in the lower extremities, an
intact cognitive function (no diagnosis of dementia and at
least seven correct answers on a ten-item Short Portable
Mental Status Questionnaire [14], ability to ambulate in-
dependently with or without the help of walking aids. The
age limits for THR (65–79 years) are standard in our
hospital and in most Swedish hospitals. We will exclude
patients with pathological fractures, and those with
rheumatoid arthritis or symptomatic osteoarthritis of
the hip. We will also exclude those who, because of severe
co-morbidities, are deemed not suitable for a THR by the
anaesthesiologist, and those who are unsuitable to partici-
pate in the study for any other reason (substance abuse,
alcoholism). Based on our previous experience in ran-
domized clinical trials in this population, [1, 5] we ex-
pect to include and receive informed consent from
approximately half of the target population (i.e. 65–79
years and fulfilling other inclusion criteria).
The baseline data of the patients’ health-related quality
of life and hip function will be obtained retrospectively
for the last week.
Surgical intervention
Surgery in both groups will be performed by a consult-
ant or a specialist experienced in both procedures
using a direct lateral approach [15] with the patient in
the lateral decubitus position. Preoperative planning
will be performed using digital software (MDesk; RSA
Biomedical AB, Umeå, Sweden). The modular CPT
(Zimmer, Warsaw, Indiana, USA) collarless, polished,
tapered femoral component manufactured from
cobalt-chromium will be used used in the cemented
group. The Bi-Metric stem (Biomet, Warsaw, Indiana,
USA) is a tapered, proximally coated (plasma-sprayed,
commercially pure [CP]) titanium femoral stem and
will be used in the uncemented group. A 32 mm
cobalt-chromium will be used for all patients.
In the acetabular component we will use a cemented
XLPE cup and a vacuum-mixed low-viscosity cement
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with gentamicin. All surgeons have a long experience
with all implants so no learning curve is expected. Low-
molecular-weight heparin (Fragmin, Pfizer, Täby,
Sweden) postoperative day 1 and for at least 10 days
postoperatively will be given as thromboprophylaxis.
Antibiotic prophylaxis with Cloxacillin 2 g (Ekvacillin;
Meda Sweden) will be given preoperatively, followed by
two additional doses during the first 24 h. Patients in
both groups will be mobilised with full weight bearing
with the aid of two crutches as tolerated and to abandon
crutches at their own convenience. After 6 weeks they
will be permitted to mobilise without further restriction.
A physiotherapist will follow all patients for the first
3 months after surgery.
Outcome measurements
Primary endpoints
The primary endpoints will be 1) the incidence of all
hip-related complications up to 2 years after surgery and
2) change in health-related quality of life assessed with
EQ-5D index (EuroQol) [16] up to 2 years. Hip-related
complications are defined as intra- and postoperative
periprosthetic fractures, dislocation, wound infection both
superficial and deep, loosening both early and late and
revision of any prosthetic implant for any reason.
Secondary endpoints
The secondary endpoints include overall mortality as
well as hip function evaluated with Harris hip score
(HHS) [17]. The score is widely used for evaluating hip
function after THA and has also been validated as a self-
reported instrument and for patients with fractures of
the femoral neck [18–20]. Other endpoints includes pain
when walking in the involved hip (measured with a
visual analogue scale (VAS) [21] and activities of daily
living (ADL) [22]. Other data collected include intraope-
rative bleeding, duration of surgery and vital signs (blood
pressure, heart rate and pulse oximetry before, during
and after stem insertion) to estimate any decrease in value
during cementing. In addition, we measure serological
markers of inflammation (Interleukin-6 [IL-6], C-reactive
protein [CRP]) and thrombosis (D-dimer) at operative
day, post-operative day (POD) 1, POD 4 and at 3 months.
We will record all general medical complications including
cardiovascular events and thromboembolism.
Radiology
Radiological analysis includes the presence of radio-
lucent lines around the stem and cup in the zones of
Gruen et al. [23] and Delee and Charnley [24]. Any cir-
cumferential radiolucent lines around the implants will be
defined as loosening. Heterotopic ossification is graded
according to the classification of Brooker et al. [25]. All
radiological evaluations will be done by an independent
radiologist not otherwise involved in the study.
Data collection and follow-ups
The primary assessment will establish that the patient
fulfils all inclusion/exclusion criteria and identify any co-
morbidity. The patients will then be interviewed by a
research nurse regarding living conditions, mobility,
activities of daily living (ADL) [22], status and health-
related quality of life according to the EQ-5D during the
last week before the fracture as a baseline. For all primary
and secondary endpoints including ADL the patients
themselves will be providing data during the study period.
It is obvious that the patients’ ability to record this
correctly while awaiting urgent surgery may be ques-
tioned. It is, however, impossible to collect these data in a
prospective manner and the method is regularly used in
patients with a fracture of the hip [1, 2, 19]. Patients who
are unable or unwilling to attend follow-ups will be inter-
viewed by telephone or they will send their answers by
mail. We will use the unique Swedish personal id-number
and collect data prospectively throughout the study
period through a combination of a search of our data-
bases, follow-ups and the Swedish Hip Arthroplasty
Register. Non hip-related adverse events (AEs) and
serious adverse events (SAEs) will be collected through-
out the study period (2 years). Although the primary
endpoints will be evaluated at 2 years, the study will
also include a 4 and 10-year follow-up. The study visits
are presented in Table 1.
Data quality assurance
The monitoring of the study and the data quality assur-
ance will be identical to the methods published in two
other study protocols from our research group [26, 27].
Briefly, we will use an external monitor to ensure that
ICH- GCP [10] and all aspects of the protocol are
followed. All study data will be collected and managed
in a digital case report form (CRF) using REDCap elec-
tronic data capture tools hosted at Karolinska Institutet
[28]. Each subject will receive a unique identification
number, which will be linked to the CRF. The data will
then be blinded correspondingly in all data analyses.
Sample size and power analysis
Prior to the study start, a sample size calculation was
done. To show non-inferiority with 80 % power of the
primary endpoint all hip-related complications between
the two groups, assuming a total complication rate of
20 %, and with a non-inferiority limit of 15 % requires
60 patients in each group. The assumed 20 % complica-
tion rate includes also minor hip-related complications
as per previously published papers ranging between 10
and 20 % [1, 2, 6]. To show non-inferiority with 80 %
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power of the primary variable health related quality of life
– HRQoL, as measured with EQ-5D requires 40 patients
in each group, and with a non-inferiority limit of 0.1, as-
suming a value of 0.73 (SD 0.18) 1 year after the sur-
gery [5]. The alpha (2-tailed) is set at 0.025 since we
have two endpoints for the power calculation. Since
this patient group has a 1-year mortality of 10 %, 70 pa-
tients in each group should be sufficient for the study.
Analysis
Analyses of outcome are based on the intention-to-treat
principle and all patients remain in their randomized
group regardless of any further surgical intervention.
Patients with missing data (i.e. EQ-5D, HHS VAS etc.)
at any of the follow-ups are analysed with the last
observation carried forward (imputed). Descriptive sta-
tistics (means and standard deviations) will be used to
describe the patient characteristics and outcome vari-
ables at the measurement points. Fisher’s exact test will
be used to test the primary endpoint. We will use the
Student’s t-test and Levene’s test for comparison of the
functional outcomes with 95 % CI presented. We will
use Kaplan-Meier survival curves with log-rank test
for patient and hip re-operation survival analysis. The
analyses will be performed with SPSS 22.0 for Mac
(SPSS, Chicago, Illinois) statistical software.
Discussion
The strengths of the study are the patient blinding and
the study design with clinically relevant outcome as the
primary endpoint. The ethical committee at Karolinska
Institutet has approved the study. An interim analysis on
the primary endpoints will be performed when half the
sample sizes in included. If there is a disproportionate
number of hip-related, or other, complications in the
uncemented group the study will be stopped. The re-
sults from the study will be disseminated to the medical
community via presentations and publications in rele-
vant medical journals. We believe the internal validity
of this trial is good due to the strict inclusion criteria,
rigorous follow-up and the blinding of the patients.
Broad exclusion criterias can affect the external validity
and generalizability of a study but they are mainly focusing
on excluding patients with malignant disease or those with
contraindications for either treatment methods as well as
patients with cognitive impairment.
Conclusion
The present trial will provide evidence for the future
choice of stem fixation for hip arthroplasty in elderly
patients below 80 years of age with a displaced femoral
neck fracture and without cognitive impairment.
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Table 1 All visits in the study
d 0 d 0 0 +1 d +4 d 5d 3 m. 1 y 2 y 4 y 10 y
Screening Inclusion Randomization
and surgery
POD1 POD4 End of
In-pt stay
Follow-up Follow-up Follow-up Follow-up Follow-up




X-ray x x x x x x
HHS x x x x x
VAS x x x x x
EQ-5D x x x x x
Adverse events x x x x x x x x
Intraoperative x
Blood test x x x x
X-ray = anterioposterior and lateral radiographs, HHS = Harris hip score, EQ-5D = Quality of life score, Intraoperative = Intraoperative measurements including blood
pressure, puls rate, pulse oxyometry before, during and after femoral stem insertion, VAS = Visual Analogue Scale for hip pain, Bloodtest = C-reactive protein (CRP),
IL-6, Hb, D-dimer
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